- Home
- CYH vs RZLT Comparison
CYH vs RZLT Comparison
Compare CYH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | RZLT |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 471.0M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CYH | RZLT |
|---|---|---|
| Price | $2.67 | $4.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $3.09 | ★ $9.80 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 23.47 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $12,485,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.69 | $2,214.20 |
| P/E Ratio | $31.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.41 | $1.07 |
| 52 Week High | $4.30 | $11.46 |
Technical Indicators
Market Signals| Indicator | CYH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 53.23 |
| Support Level | $2.74 | $3.58 |
| Resistance Level | $3.02 | $5.43 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.45 | 55.52 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.